acriflavine / Johns Hopkins University - LARVOL DELTA

Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice. (PubMed, J Clin Invest) - "However, while the HIF-inhibitor acriflavine prevented retinal vascular hyperpermeability in diabetic mice for several months following a single intraocular injection, accumulation of acriflavine in the retina resulted in retinal toxicity over time, raising concerns for its use in patients...Intraocular administration of 32-134D prevented retinal neovascularization and vascular hyperpermeability in mice. These results provide the foundation for clinical studies assessing 32-134D for the treatment of patients with diabetic eye disease."

Journal • Preclinical • Age-related Macular Degeneration • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders